Protalix Biotherapeutics, INC 10-Q quarterly reports

Protalix BioTherapeutics announces a significant surge in revenue and net income for the second quarter of 2026, driven by strong sales of Elfabrio and Elelyso.

Protalix BioTherapeutics reports a significant increase in total revenue for Q1 2026, driven by license and R&D services, alongside a substantial improvement in operating income.

Protalix BioTherapeutics reported a net income of $2.355 million for Q3 2025, driven by increased sales to Fiocruz and R&D services, while advancing its PRX-115 gout treatment to Phase 2 clinical trials.

Protalix BioTherapeutics reports significant revenue growth driven by Elfabrio sales and reduced net loss, while advancing its pipeline and securing additional capital.

Protalix BioTherapeutics reports a significant revenue increase of 170% in Q1 2025, driven by higher sales of Elelyso and progress in its clinical pipeline.

Protalix BioTherapeutics reports a mixed third quarter with increased product sales offset by a decrease in R&D revenue, while highlighting the full repayment of convertible notes and progress in clinical trials.

Protalix BioTherapeutics reports a net loss for the second quarter of 2024, with a decrease in revenue from license and R&D services, but an increase in sales to Brazil and Pfizer.

Protalix BioTherapeutics reported a net loss of $4.6 million for the first quarter of 2024, with a decrease in revenue compared to the same period in 2023.